Aclaris Therapeutics (ACRS)
NASDAQ:ACRS
Want to see ACRS full AI Analyst Report?
Total Valuation
Aclaris Therapeutics has a market cap or net worth of $614.52M. The enterprise value is $519.62M.
Market Cap$614.52M
Enterprise Value$519.62M
Share Statistics
Aclaris Therapeutics has 139,663,680 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding139,663,680
Owned by Insiders12.34%
Owned by Institutions48.90%
Financial Efficiency
Aclaris Therapeutics’s return on equity (ROE) is -0.63 and return on invested capital (ROIC) is -57.70%.
Return on Equity (ROE)-0.63
Return on Assets (ROA)-0.40
Return on Invested Capital (ROIC)-57.70%
Return on Capital Employed (ROCE)-0.58
Revenue Per Employee128.30K
Profits Per Employee-1.06M
Employee Count61
Asset Turnover0.05
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Aclaris Therapeutics is ―. Aclaris Therapeutics’s PEG ratio is 0.08.
PE Ratio―
PS Ratio47.18
PB Ratio3.58
Price to Fair Value3.58
Price to FCF-7.84
Price to Operating Cash Flow-10.98
PEG Ratio0.08
Income Statement
In the last 12 months, Aclaris Therapeutics had revenue of 7.83M and earned -64.92M in profits. Earnings per share was -0.53.
Revenue7.83M
Gross Profit5.74M
Operating Income-76.38M
Pretax Income-64.92M
Net Income-64.92M
EBITDA-64.47M
Earnings Per Share (EPS)-0.53
Cash Flow
In the last 12 months, operating cash flow was -52.20M and capital expenditures -81.00K, giving a free cash flow of -52.27M billion.
Operating Cash Flow-52.20M
Free Cash Flow-52.27M
Free Cash Flow per Share-0.37
Dividends & Yields
Aclaris Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.57
52-Week Price Change244.96%
50-Day Moving Average4.12
200-Day Moving Average2.96
Relative Strength Index (RSI)49.67
Average Volume (3m)1.11M
Important Dates
Aclaris Therapeutics upcoming earnings date is Aug 12, 2026, Before Open (Confirmed).
Last Earnings DateMay 12, 2026
Next Earnings DateAug 12, 2026
Ex-Dividend Date―
Financial Position
Aclaris Therapeutics as a current ratio of 5.28, with Debt / Equity ratio of 1.38%
Current Ratio5.28
Quick Ratio5.28
Debt to Market Cap<0.01
Net Debt to EBITDA0.28
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Aclaris Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Aclaris Therapeutics EV to EBITDA ratio is -5.45, with an EV/FCF ratio of -7.46.
EV to Sales44.90
EV to EBITDA-5.45
EV to Free Cash Flow-7.46
EV to Operating Cash Flow-7.46
Balance Sheet
Aclaris Therapeutics has $105.42M in cash and marketable securities with $1.99M in debt, giving a net cash position of $103.43M billion.
Cash & Marketable Securities$105.42M
Total Debt$1.99M
Net Cash$103.43M
Net Cash Per Share$0.74
Tangible Book Value Per Share$0.84
Margins
Gross margin is 76.34%, with operating margin of -975.91%, and net profit margin of -829.58%.
Gross Margin76.34%
Operating Margin-975.91%
Pretax Margin-829.58%
Net Profit Margin-829.58%
EBITDA Margin-823.78%
EBIT Margin-829.58%
Analyst Forecast
The average price target for Aclaris Therapeutics is $10.38, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$10.38
Price Target Upside144.12% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast-52.94%
EPS Growth Forecast59.88%